A detailed history of Jump Financial, LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Jump Financial, LLC holds 72,152 shares of QURE stock, worth $417,038. This represents 0.01% of its overall portfolio holdings.

Number of Shares
72,152
Previous 75,017 3.82%
Holding current value
$417,038
Previous $336,000 5.65%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.78 - $10.12 $10,829 - $28,993
-2,865 Reduced 3.82%
72,152 $355,000
Q2 2024

Aug 14, 2024

SELL
$4.39 - $5.43 $108,253 - $133,898
-24,659 Reduced 24.74%
75,017 $336,000
Q1 2024

May 13, 2024

SELL
$4.82 - $6.93 $44,372 - $63,797
-9,206 Reduced 8.46%
99,676 $518,000
Q4 2023

Oct 21, 2024

SELL
$5.63 - $8.27 $77,333 - $113,596
-13,736 Reduced 11.2%
108,882 $737,000
Q4 2023

Feb 07, 2024

SELL
$5.63 - $8.27 $77,333 - $113,596
-13,736 Reduced 11.2%
108,882 $737,000
Q3 2023

Oct 21, 2024

BUY
$6.71 - $11.83 $502,773 - $886,410
74,929 Added 157.12%
122,618 $822,000
Q3 2023

Nov 07, 2023

BUY
$6.71 - $11.83 $822,766 - $1.45 Million
122,618 New
122,618 $822,000
Q1 2023

Oct 21, 2024

SELL
$18.7 - $23.07 $511,033 - $630,456
-27,328 Reduced 36.43%
47,689 $960,000
Q1 2023

May 03, 2023

BUY
$18.7 - $23.07 $276,516 - $341,136
14,787 Added 44.94%
47,689 $960,000
Q4 2022

Feb 13, 2023

BUY
$18.12 - $27.32 $596,184 - $898,882
32,902 New
32,902 $745,000
Q3 2021

Nov 12, 2021

SELL
$26.01 - $38.22 $704,871 - $1.04 Million
-27,100 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$29.97 - $37.17 $812,187 - $1.01 Million
27,100 New
27,100 $835,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $270M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.